130798-51-5 Usage
Description
MDL-29951 is a compound that acts as an antagonist of N-methyl-D-aspartate (NMDA) receptors, specifically targeting the glycine binding site with high affinity (Ki = 140 nM). It is effective both in vitro and in vivo, and is known for its ability to block NMDA receptor-dependent convulsions in audiogenic seizure-susceptible DBA/2J mice. Additionally, MDL-29951 serves as an agonist for the G protein-coupled receptor GPR17, which is believed to play a role in oligodendrocyte differentiation and myelin formation/repair.
Uses
Used in Pharmaceutical Research:
MDL-29951 is used as a research tool for studying the role of the glycine site of the NMDA receptor in neurological signaling. Its ability to block NMDA receptor-dependent convulsions makes it a valuable compound for understanding the underlying mechanisms of neurological disorders and potential therapeutic interventions.
Used in Neurological Disorder Treatment:
MDL-29951 is used as a potential therapeutic agent for treating neurological disorders associated with NMDA receptor dysfunction, such as epilepsy and other seizure-related conditions. Its antagonistic action on the NMDA receptor may help in reducing the frequency and severity of seizures.
Used in Myelin Formation and Repair:
MDL-29951 is used as a potential therapeutic agent for promoting oligodendrocyte differentiation and myelin formation/repair. Its agonistic action on the GPR17 receptor suggests that it may be useful in treating conditions related to demyelination, such as multiple sclerosis.
Used in Drug Delivery Systems:
While not explicitly mentioned in the provided materials, MDL-29951's potential applications in drug delivery systems could be explored, similar to the use of gallotannin in improving drug delivery, bioavailability, and therapeutic outcomes. This would involve developing novel drug delivery systems to enhance the efficacy and targeting of MDL-29951 in treating neurological disorders and conditions related to myelin formation/repair.
References
1) Hennen?et al. (2013),?Decoding Signaling and Function of the Orphan Protein-Coupled Receptor GPR17 with a small molecule agonist; Sci. Signal.,?6?ra93
2) Salituro?et al. (1992)?3-(2-Carboxyindol-3-yl)propionic Acid-Based Antagonists of the N-Methyl-D-aspartic Acid Receptor Associated Glycine Binding Site; J. Med. Chem.,?35?1791
Check Digit Verification of cas no
The CAS Registry Mumber 130798-51-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,7,9 and 8 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 130798-51:
(8*1)+(7*3)+(6*0)+(5*7)+(4*9)+(3*8)+(2*5)+(1*1)=135
135 % 10 = 5
So 130798-51-5 is a valid CAS Registry Number.
130798-51-5Relevant articles and documents
Improved synthesis of 4-/6-substituted 2-carboxy-1H-indole-3-propionic acid derivatives and structure-activity relationships as GPR17 agonists
Baqi, Younis,Alshaibani, Samer,Ritter, Kirsten,Abdelrahman, Aliaa,Spinrath, Andreas,Kostenis, Evi,Mueller, Christa E.
, p. 86 - 92 (2014/01/06)
The orphan G protein-coupled receptor GPR17 was shown to be involved in myelin repair and has been proposed as a novel drug target for the treatment of brain and spinal cord injury and for multiple sclerosis. Recently, 3-(2-carboxy-4,6-dichloro-indol-3-yl
3-(2-Carboxyindol-3-yl)propionic Acid Derivatives: Antagonists of the Strychnine-Insensitive Glycine Receptor Associated with the N-Methyl-D-aspartate Receptor Complex
Salituro, Francesco G.,Harrison, Boyd L.,Baron, Bruce M.,Nyce, Philip L.,Stewart, Kenneth T.,McDonald, Ian A.
, p. 2944 - 2946 (2007/10/02)
-
